Eagle Pharmaceuticals (EGRX) Tops Q1 EPS by 27c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/6/2026
- Dow jumps to record closing high after soft US jobs data, Nasdaq down with chip shares
- Goldman's Garrett sees investors dialing back tech exposure into H2
- AI chip winners may face tougher road ahead as hyperscalers catch up: JPM
- Oil gains on short-covering buys ahead of US holiday
- Rivian stock jumps 5% on raised delivery outlook
Eagle Pharmaceuticals Reports First Quarter 2020 Results
May 11, 2020 6:50 AM EDT-- Q1 2020 net loss was ($0.21) per basic and diluted share and adjusted non-GAAP net income was $0.86 per basic and $0.84 per diluted share --
-- Advanced novel fulvestrant product candidate, EA-114, which has the potential to enhance estrogen receptor (ER) inhibition in advanced hormone-receptor (HR)-positive breast cancer --
-- Received favorable patent litigation decision for BENDEKA® (bendamustine hydrochloride injection); ANDA holders to be enjoined from launching prior to 2031 --
-- Preparing for multiple potential product launches in the next three years; 13 ongoing initiatives underway including six additional... More
